 |
Video: What is a Stock Split?
|
 |
Vertex Pharmaceuticals Incorporated is a global biotechnology company. Co. is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. According to our Vertex Pharmaceuticals stock split history records, Vertex Pharmaceuticals has had 1 split. | |
 |

Vertex Pharmaceuticals (VRTX) has 1 split in our Vertex Pharmaceuticals stock split history database. The split for VRTX took place on August 24, 2000. This was a 2 for 1 split, meaning for each share of VRTX owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.
When a company such as Vertex Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the Vertex Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vertex Pharmaceuticals shares, starting with a $10,000 purchase of VRTX, presented on a split-history-adjusted basis factoring in the complete Vertex Pharmaceuticals stock split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/18/2015 |
|
End date: |
02/14/2025 |
|
Start price/share: |
$113.57 |
|
End price/share: |
$459.00 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
304.16% |
|
Average Annual Total Return: |
14.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$40,404.95 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
08/24/2000 | 2 for 1 |
|
 |